RTGN Stock Overview
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
RetinalGenix Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$4.49 |
| 52 Week Low | US$3.00 |
| Beta | -2.88 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 16.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| RTGN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.3% |
| 1Y | n/a | -0.6% | 24.2% |
Return vs Industry: Insufficient data to determine how RTGN performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how RTGN performed against the US Market.
Price Volatility
| RTGN volatility | |
|---|---|
| RTGN Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RTGN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RTGN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Jerry Katzman | retinalgenix.com |
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX, a resolution retinal imaging diabetic screening system that provides a 200-degree field of view without requiring pupil dilation; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is based in Petaluma, California.
RetinalGenix Technologies Inc. Fundamentals Summary
| RTGN fundamental statistics | |
|---|---|
| Market cap | US$62.25m |
| Earnings (TTM) | -US$2.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-29.8x
P/E RatioIs RTGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RTGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.09m |
| Earnings | -US$2.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -36.0% |
How did RTGN perform over the long term?
See historical performance and comparison